Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
The IFNL4 ss469415590 polymorphism has recently be shown to better predict treatment response in chronic hepatitis than the IL28B rs12979860 variant. However, no data exist in patients with HIV/hepatitis C virus (HCV) coinfection. Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(-) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(-) individuals but not in HIV(+)/HCV(+) patients. Thus, effects of the IFNL4 variant may differ in HIV(+) and HIV(-) patients.
aDepartment of Internal Medicine I, German Center for Infection Research, University of Bonn, Bonn bMedical Center for Infectious Diseases (MIB), Berlin cPraxis am Ebertplatz, Cologne dCenter for HIV and Hepatogastroenterology, Duesseldorf eICH, Hamburg, Germany. *Benjamin Krämer and Hans Dieter Nischalke contributed equally to the writing of this article.
Benjamin
B
Krämer
Hans Dieter
HD
Nischalke
Christoph
C
Boesecke
Patrick
P
Ingiliz
Esther
E
Voigt
Stefan
S
Mauss
Hans-Jürgen
HJ
Stellbrink
Axel
A
Baumgarten
Juergen K
JK
Rockstroh
Ulrich
U
Spengler
Jacob
J
Nattermann
D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007378:Interleukins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; C579163:IFNL4 protein, human; D000095022:Interferon Lambda